|
**Overview**: Allergy Phadiatop Pediatric Panel**Introduction**: The Allergy Phadiatop Pediatric Panel is a diagnostic tool designed to screen for inhalant allergies in children using serum samples. In India, pediatric allergic rhinitis affects ~22-23.5 percent of adolescents per ISAAC studies, with asthma high in children and Phadiatop positivity ~50-70 percent in symptomatic respiratory cases. Dominant triggers include dust mite and cockroach, with pollen/mold varying regionally. Symptoms include sneezing, nasal congestion, wheezing, and recurrent infections, impacting school performance and growth. High morbidity from underdiagnosis in school children, limited pediatric allergy access in rural areas. Per immunology practices aligned with ICMR guidelines, the test employs immunoassay for Phadiatop pediatric mix analysis over 1-2 days with high sensitivity/specificity, valuable as a broad screening tool for inhalant atopy in children. This diagnostic falls under pediatric allergy screening and targets children with suspected inhalant allergies, addressing accurate detection to guide further testing and management. With morbidity elevated due to underdiagnosis, the test supports public health efforts by enabling early identification, facilitating management, and reducing long-term respiratory burden. Its serum-based approach ensures reliable detection in pediatric settings.**Other Names**: Phadiatop Ped Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Adapted for pediatric use; in India, relevance with high childhood allergic disease burden.**Purpose**: The test screens for 1 parameter (Phadiatop pediatric mix) to guide assessment of inhalant allergy, identify atopy, inform further specific testing.**Test Parameters**: 1. Phadiatop (Pediatric Inhalant Allergens Mix).**Pretest Condition**: No fasting required; parents should report child's persistent rhinitis or asthma symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Parents should provide details on child's symptoms, home environment, family atopy, or school absenteeism.**Consent**: Written informed consent from parent/guardian is required, detailing the test's purpose, potential risks of untreated allergies including recurrent infections, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent viral infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible inhalant atopy, necessitating further investigation like specialist consultation or specific allergen testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: Pediatric allergists or pulmonologists should be consulted for case management, treatment planning, and coordination with child health programs.**Additional Supporting Tests**: Specific IgE panels or spirometry for confirmation.**Test Limitations**: The test may produce false negatives in low exposure or false positives in asymptomatic sensitization, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: ICMR Pediatric Allergy Guidelines 2023, ISAAC India Studies 2023-2025. |
